Draft:Sehgal-v1
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Cnrowley (talk | contribs) 2 seconds ago. (Update) |
Surendra Nath Sehgal | |
|---|---|
| Born | 1932 |
| Died | January 21, 2003 |
| Education | Banaras Hindu University, University of Bristol |
| Employer | Wyeth |
| Scientific career | |
| Thesis | A study of some factors influencing the action of Anti-biotics on Micro-organisms : with special reference to the action of Streptomycin on Staphylococcus aureus |
| Doctoral advisor | Alan H. Linton |
Surendra Nath Sehgal (1932–2003) was an Indian-Canadian-American microbiologist and pharmaceutical scientist most widely known for his discovery and development of Rapamycin (Sirolimus), a immunosuppressant drug widely used in organ transplantation. Rapamycin has also attracted attention as a potential anti-cancer and anti-aging drug.
https://journals.lww.com/indianjcancer/fulltext/2017/54040/surendra_nath_sehgal__a_pioneer_in_rapamycin.24.aspx
Early Life and Education
[edit]Surendra (Suren) Nath Sehgal, as born in Khushab in pre-partition India (now Pakistan). His father, Sita Ram Sehgal, owned a pharmaceutical factory, but relocated to New Delhi in 1947 after the Partition of India.
Sehgal completed a B.Pharm in 1952 and an M.Pharm in 1953 from Banaras Hindu University. At 21, he moved to England to pursue his Ph.D. in Microbiology and Immunology at the University of Bristol, graduating in 1957.
Career Highlights
[edit]After completing his Ph.D., Sehgal accepted a postdoctoral fellowship at the National Research Council of Canada. In 1959, he joined Ayerst Research Laboratories in Montreal, becoming part of the Department of Microbiology.
In 1964, a Canadian research expedition collected soil samples from Easter Island.[1] These soil samples contained a bacterium, Streptomyces hydroscopicus AY B-994, which showed anti-fungal properties.[2] Isolates of these bacteria were obtained Suren and his team at Ayerst. They found that the activity of these bacteria was the result of a novel compound, later named Rapamycin.
Ayerst merged with Wyeth in 1983 and relocated their research operations to the United States and Sehgal relocated to Princeton, New Jersey to continue his work at Wyeth.[1] Sehgal stored vials of the rapamycin-producing bacteria in his home freezer to prevent their destruction. In response to Sehgal's advocacy, new management at Wyeth restored support for development of rapamycin as a drug in 1987. This eventually led to the FDA approval of rapamycin as an immunosuppressant to prevent organ transplant rejection in 1999. The drug is sold as RAPAMUNE (sirolimus).
Awards and Distinctions
[edit]- 1995 Clinical Recognition Award: “For ideas and scientific achievements that have contributed to discovery and development of rapamycin ”
- 1997 Lifetime Achievement Award. “For his outstanding landmark contribution in discovering an effective immunosuppressive drug for organ transplantation.” Awarded by The Indian Society of Organ Transplantation.[3]
- 1997 Elected Fellow of American Academy of Microbiology
- 2000 Lifetime Achievement Award. The Canadian Transplantation Society[4]
Personal Life and Legacy
[edit]Sehgal became a Canadian citizen while he worked for Ayest in Montreal. He later became a dual citizen of Canada and the United States after relocating to Princeton.
Sehgal was diagnosed with stage 4 metastatic colon cancer in 1998. He died at home in Seattle on January 21, 2003.[5][6]
References
[edit]https://www.sehgal.net/surenshistory.htm
- ^ Powers, Ted (November 2022). "The origin story of rapamycin: systemic bias in biomedical research and cold war politics". Molecular Biology of the Cell. 33 (13): pe7. doi:10.1091/mbc.E22-08-0377. ISSN 1059-1524. PMC 9634974. PMID 36228182.
- ^ Vézina, Claude; Kudelski, Alicia; Sehgal, S. N. (1975). "RAPAMYCIN (AY-22, 989), A NEW ANTIFUNGAL ANTIBIOTIC I. TAXONOMY OF THE PRODUCING STREPTOMYCETE AND ISOLATION OF THE ACTIVE PRINCIPLE". The Journal of Antibiotics. 28 (10): 721–726. doi:10.7164/antibiotics.28.721. ISSN 0021-8820.
- ^ Samanta, Debopam (October–December 2017). "Surendra Nath Sehgal: A pioneer in rapamycin discovery". Indian Journal of Cancer. 54 (4): 697–698. doi:10.4103/ijc.IJC_84_18. ISSN 0019-509X. PMID 30082562.
- ^ "Canadian Society of Transplantation - Past Major Award Recipients". www.cst-transplant.ca. Retrieved 2024-12-18.
- ^ Samanta, Debopam (2017). "Surendra Nath Sehgal: A pioneer in rapamycin discovery". Indian Journal of Cancer. 54 (4): 697–698. doi:10.4103/ijc.IJC_84_18. ISSN 0019-509X. PMID 30082562.
- ^ Hobby, Gerren; Clark, Rebecca; Woywodt, Alexander (2022-09-22). "A treasure from a barren island: the discovery of rapamycin". Clinical Kidney Journal. 15 (10): 1971–1972. doi:10.1093/ckj/sfac116. ISSN 2048-8505. PMC 9494524. PMID 36158154.